Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Up 3.8%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s stock price shot up 3.8% on Tuesday . The company traded as high as 0.28 and last traded at 0.27. 292,900 shares changed hands during trading, a decline of 52% from the average session volume of 615,489 shares. The stock had previously closed at 0.26.

Perspective Therapeutics Stock Performance

The company has a market cap of $75.75 million, a price-to-earnings ratio of -3.00 and a beta of 1.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.72 and a quick ratio of 3.59.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings data on Friday, August 11th. The company reported -0.04 earnings per share for the quarter, missing analysts’ consensus estimates of -0.03 by -0.01. The company had revenue of 2.09 million for the quarter, compared to analysts’ expectations of 2.61 million. Perspective Therapeutics had a negative net margin of 239.46% and a negative return on equity of 19.46%. As a group, sell-side analysts forecast that Perspective Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wealth Effects LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $30,000. Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $42,000. Taylor & Morgan Wealth Management LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $157,000. Finally, Perkins Capital Management Inc. bought a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $731,000. Hedge funds and other institutional investors own 23.20% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.